先声药业：就SIM0613签订许可协议 合同包括4,500万美元的首付款

Core Viewpoint - The company has entered into an exclusive licensing agreement with Ipsen Pharma SAS for the antibody-drug conjugate SIM0613, targeting LRRC15, which will allow Ipsen to develop, manufacture, and commercialize the drug outside Greater China [1] Group 1 - The agreement grants Ipsen global exclusive rights for the development, production, and commercialization of SIM0613 in regions outside Greater China [1] - The company is entitled to receive up to $1.06 billion in total payments, which includes an upfront payment of $45 million [1] - Additional payments will be based on research, regulatory, and commercialization milestones, along with tiered royalties on sales [1]